Xu He

发表

Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer.

S. Yie, K. Xie, Be Lou, 2009, Lung cancer.

Bibliometric Analysis of γδ T Cells as Immune Regulators in Cancer Prognosis

Xu He, Li-Gong Lu, Bingli Liu, 2022, Frontiers in Immunology.

OTT_A_220453 10811..10825

A. Jia, Meixiao Zhan, Xu He, 2019 .

Camellia nitidissima Chi Extract Potentiates the Sensitivity of Gastric Cancer Cells to Paclitaxel via the Induction of Autophagy and Apoptosis

A. Jia, Meixiao Zhan, Xu He, 2019, OncoTargets and therapy.

POPDC3 is a potential biomarker for prognosis and radioresistance in patients with head and neck squamous cell carcinoma

Ligong Lu, Hongyi Liu, Meixiao Zhan, 2019, Oncology letters.

Nano-enabled coordination platform of bismuth nitrate and cisplatin prodrug potentiates cancer chemoradiotherapy via DNA damage enhancement.

Meixiao Zhan, Xu He, Xinfeng Tang, 2021, Biomaterials science.

Development of a prognostic model based on immunogenomic landscape analysis of hepatocellular carcinoma

Fujun Zhang, Meixiao Zhan, Xu He, 2021 .

Homologous-targeted and tumor microenvironment-activated hydroxyl radical nanogenerator for enhanced chemoimmunotherapy of non-small cell lung cancer

Ligong Lu, Meixiao Zhan, Xu He, 2021 .

Asiatic acid alleviates liver fibrosis via multiple signaling pathways based on integrated network pharmacology and lipidomics.

Lei Zhang, Yong Li, Xu He, 2022, European journal of pharmacology.

Retraction Note to: Clinical value of circulating tumor cells for the prognosis of postoperative transarterial chemoembolization therapy

Xu He, Yong Li, Wei Zhao, 2014, Medical Oncology.

RETRACTED ARTICLE: Clinical value of circulating tumor cells for the prognosis of postoperative transarterial chemoembolization therapy

Xu He, Yong Li, Wei Zhao, 2014, Medical Oncology.

Detection of Survivin-Expressing Circulating Cancer Cells (CCCs) in Peripheral Blood of Patients with Gastric and Colorectal Cancer Reveals High Risks of Relapse

S. Yie, Be Lou, S. Ye, 2008, Annals of Surgical Oncology.

Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development

Yu Zhang, Meixiao Zhan, Xu He, 2022, Frontiers in Oncology.

Native Mitochondria-Targeting polymeric nanoparticles for mild photothermal therapy rationally potentiated with immune checkpoints blockade to inhibit tumor recurrence and metastasis

Xianglong Hu, Siyu Lu, Ligong Lu, 2021 .

Environmentally Stable, Stretchable, Adhesive, and Conductive Organohydrogels with Multiple Dynamic Interactions as High-Performance Strain and Temperature Sensors.

Weizhong Yuan, Liduo Rong, Meixiao Zhan, 2022, ACS applied materials & interfaces.

Dual‐Cascade Activatable Nanopotentiators Reshaping Adenosine Metabolism for Sono‐Chemodynamic‐Immunotherapy of Deep Tumors

Ligong Lu, Jingchao Li, Meixiao Zhan, 2023, Advanced science.

Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway

Minshan Chen, Meixiao Zhan, Xu He, 2019, Artificial cells, nanomedicine, and biotechnology.

Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data

Fujun Zhang, Ligong Lu, Meixiao Zhan, 2021, Aging.

The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.

Xu He, Yong Li, Wei Zhao, 2013, Asian Pacific journal of cancer prevention : APJCP.

Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma

Kai Chen, Meixiao Zhan, Xu He, 2017, Oncology letters.

Transhepatic arterial chemoembolizations with lobaplatin-eluting microspheres for the treatment of unresectable hepatocellular carcinoma

Xu He, Yong Li, Li-Gong Lu, 2018 .

An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients

Xu He, Yong Li, Li-Gong Lu, 2016, Hepatology International.

MiR-135b promotes HCC tumorigenesis through a positive-feedback loop.

Ligong Lu, Meixiao Zhan, Xu He, 2020, Biochemical and biophysical research communications.

Interactome analysis of gene expression profiles identifies CDC6 as a potential therapeutic target modified by miR-215-5p in hepatocellular carcinoma

Ligong Lu, Meixiao Zhan, Xu He, 2020, International journal of medical sciences.

LncRNA HOXA11‐AS promotes hepatocellular carcinoma progression by repressing miR‐214‐3p

Haihe Wang, Ligong Lu, Meixiao Zhan, 2018, Journal of cellular and molecular medicine.

Bidirectional modulation of insulin action by reactive oxygen species in 3T3-L1 adipocytes

L. Luo, Ligong Lu, Meixiao Zhan, 2018, Molecular medicine reports.

The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib

Meixiao Zhan, Xu He, Yong Li, 2014, Medical Oncology.

LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p.

Ligong Lu, Meixiao Zhan, Xu He, 2019, American journal of translational research.

Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial

Xu He, Yong Li, Wei Zhao, 2015, Journal of Cancer Research and Clinical Oncology.

Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Ligong Lu, Meixiao Zhan, Xu He, 2014, Journal of vascular and interventional radiology : JVIR.

Fabrication of thermoresponsive magnetic micelles from amphiphilic poly(phenyl isocyanide) and Fe3O4 nanoparticles for controlled drug release and synergistic thermochemotherapy

Weizhong Yuan, Meixiao Zhan, Xu He, 2021 .

Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer.

X. Yi, Y. Guan, Ligong Lu, 2020, Journal of gastrointestinal oncology.

Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma

Meixiao Zhan, Xu He, Yong Li, 2014, Tumor Biology.

DBFU-Net: Double branch fusion U-Net with hard example weighting train strategy to segment retinal vessel

J. Zhang, Ligong Lu, Meixiao Zhan, 2022, PeerJ Comput. Sci..

Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.

Meixiao Zhan, Jiaping Li, Xu He, 2014, Asian Pacific journal of cancer prevention : APJCP.

Double C-Arm Digital Subtraction Angiography Guidance During Transjugular Intrahepatic Portosystemic Shunt Placement

Xu He, Jian-wen Huang, Weiguo Xu, 2023, BMC Gastroenterology.

Usp7 promotes medulloblastoma cell survival and metastasis by activating Shh pathway.

Ligong Lu, Meixiao Zhan, Xu He, 2017, Biochemical and biophysical research communications.

Clinical efficacy of CT-guided 125I brachytherapy in patients with local residual or recurrent hepatocellular carcinoma after thermal ablation

F. Gao, Fujun Zhang, Xu He, 2022, Insights into Imaging.

Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma

Xu He, Yong Li, Wei Zhao, 2013, Medical Oncology.

Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial

Xu He, Yong Li, Wei Zhao, 2015, Oncology.

Identification of hub genes in hepatocellular carcinoma using integrated bioinformatic analysis

Ligong Lu, Meixiao Zhan, Xu He, 2020, Aging.

Amphiphilic Dendrimer Doping Enhanced pH‐Sensitivity of Liposomal Vesicle for Effective Co‐delivery toward Synergistic Ferroptosis–Apoptosis Therapy of Hepatocellular Carcinoma

Zhao Zhang, Ligong Lu, Xu He, 2023, Advanced healthcare materials.

VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization

Ligong Lu, Meixiao Zhan, Xu He, 2023, Journal of Gastroenterology.